Accelerating drug development through collaboration: The Hepatitis C drug development advisory group

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 162-165

  Hutchison, C ^a   Kwong, A ^b   Ray, S ^c   Struble, K ^d   Swan, T ^e   Miller, V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b InnovaTID   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; BOCEPREVIR; LEDIPASVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ARTICLE; CONSENSUS; DRUG INDUSTRY; FUNDING; HEPATITIS C; HUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADVISORY COMMITTEES; ANIMALS; ANTIVIRAL AGENTS; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84904857264     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.113     Document Type: Article

References (5)

1. Miller, V. The forum for collaborative HIV research: A model for an integrated and inclusive approach to clinical research and drug development. Clin. Pharmacol. Ther. 86, 332-335 (2009
2. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. & Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of agespecific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013
3. Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49, 1335-1374 (2009
4. Schinazi, R., Halfon, P., Marcellin, P. & Asselah, T. HCV direct-Acting antiviral agents: The best interferon-free combinations. Liver Int. 34 (suppl. 1), 69-78 (2014
5. Kwong, A.D. et al.; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG). Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG. Gastroenterology 140, 755-760 (2011.